Myostatin Is a Quantifiable Biomarker for Monitoring Pharmaco-gene Therapy in Duchenne Muscular Dystrophy

Recently, several promising treatments have emerged for neuromuscular disorders, highlighting the need for robust biomarkers for monitoring therapeutic efficacy and maintenance of the therapeutic effect. Several studies have proposed circulating and tissue biomarkers, but none of them has been valid...

Descripción completa

Detalles Bibliográficos
Autores principales: Mariot, Virginie, Le Guiner, Caroline, Barthélémy, Inès, Montus, Marie, Blot, Stéphane, Torelli, Silvia, Morgan, Jennifer, Muntoni, Francesco, Voit, Thomas, Dumonceaux, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363622/
https://www.ncbi.nlm.nih.gov/pubmed/32695843
http://dx.doi.org/10.1016/j.omtm.2020.06.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363622/
https://www.ncbi.nlm.nih.gov/pubmed/32695843
http://dx.doi.org/10.1016/j.omtm.2020.06.016

Ejemplares similares